Original Article

You have full text access to this OnlineOpen article

A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy

  1. Kan Yonemori M.D.1,
  2. Noriyuki Katsumata M.D.1,†,*,
  3. Noboru Yamamoto M.D.1,
  4. Takahiro Kasamatsu M.D.2,
  5. Takuro Yamada M.D.2,
  6. Ryuichiro Tsunematsu M.D.2,
  7. Yasuhiro Fujiwara M.D.1

Article first published online: 26 JUL 2005

DOI: 10.1002/cncr.21287

Issue

Cancer

Cancer

Volume 104, Issue 6, pages 1204–1212, 15 September 2005

Additional Information

How to Cite

Yonemori, K., Katsumata, N., Yamamoto, N., Kasamatsu, T., Yamada, T., Tsunematsu, R. and Fujiwara, Y. (2005), A phase I study and pharmacologic evaluation of irinotecan and carboplatin for patients with advanced ovarian carcinoma who previously received platinum-containing chemotherapy. Cancer, 104: 1204–1212. doi: 10.1002/cncr.21287

Author Information

  1. 1

    Breast and Medical Oncology Division, National Cancer Center Hospital, Tokyo, Japan

  2. 2

    Division of Gynecologic Oncology, National Cancer Center Hospital, Tokyo, Japan

  1. †

    Fax: (011) 81 335423815

*Breast and Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

Publication History

  1. Issue published online: 31 AUG 2005
  2. Article first published online: 26 JUL 2005
  3. Manuscript Received: 9 DEC 2005
  4. Manuscript Accepted: 11 MAY 2005
  5. Manuscript Revised: 20 APR 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (187K)

REFERENCES

  • 1
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with Stage III and IV ovarian cancer. N Engl J Med. 1996; 334: 1–6.
  • 2
    Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected Stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003; 21: 3194–3200.
  • 3
    Misawa T, Kikkawa F, Maeda O, et al. Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells. Jpn J Cancer Res. 1995; 86: 88–94.
  • 4
    Kano Y, Akutsu M, Suzuki K, Yoshida M. Effects of carboplatin in combination with other anticancer agents on human leukemia cell lines. Leukemia Res. 1993; 17: 113–119.
  • 5
    Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer. 1992; 50: 604–610.
    Direct Link:
  • 6
    Bodurka DC, Levenback C, Wolf JK, et al. Phase II trial of irinotecan in patient with metastatic epithelial ovarian cancer or peritoneal cancer. J Clin Oncol. 2003; 21, 291–297.
  • 7
    Evans BD, Raju KS, Calvert AH, Harland SJ, Wiltshaw E. Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma. Cancer Treat Rep. 1983; 67: 997–1000.
  • 8
    Leyvraz S, Ohnuma T, Lassus M, Holland JF. Phase 1 study of carboplatin in patients with advanced cancer, intermittent intravenous bolus, and 24-hour infusion. J Clin Oncol. 1985; 3: 1385–1392.
  • 9
    Jordrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992; 10: 520–528.
  • 10
    Calvert AH, Harland SJ, Newell DR, et al. Early clinical studies with cisdiammine-1,1-cyclobutane dicarboxylate platinum II. Cancer Chemother Pharmacol. 1982; 9: 140–147.
  • 11
    Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995; 87: 573–580.
  • 12
    Fujiwara Y, Takahashi T, Yamakido M, Ohune T, Tsuya T, Egorin MJ. Re: prediction of carboplatin clearance from standard morphological and biological patients characteristics. J Natl Cancer Inst. 1997; 89: 260–261.
  • 13
    Minami H, Ando Y, Saka H, Shimokata K. Re: prediction of carboplatin clearance from standard morphological and biological patients characteristics. J Natl Cancer Inst. 1997; 89: 968–969.
  • 14
    Okamoto H, Nagamoto A, Kunitoh H, Kunikane H, Watanabe K. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae. Cancer Chemother Pharmacol. 1998; 42: 307–312.
  • 15
    Donahue A, McCune JS, Faucette S, et al. Measured versus estimated glomerular filtration rate in the Carver equation: influence on carboplatin dosing. Cancer Chemother Pharmacol. 2001; 47: 373–379.
  • 16
    Dooley MJ, Poole SG, Rishchin D, Webster LK. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate. Eur J Cancer. 2002; 38: 44–51.
  • 17
    Fukuda M, Oka M, Soda H, et al. Phase I study of irinotecan combined with carboplatin in previously untreated solid cancers. Clin Cancer Res. 1999; 5: 3963–3969.
  • 18
    Ando Y, Minami H, Saka H, Ando M, Sugiura S, Sakai S, Shimokata K. Adjustment of creatinine clearance of improves accuracy of Calvert's formula for carboplatin dosing. Br J Cancer. 1997; 76: 1067–1071.
  • 19
    Ozols RF. Treatment of recurrent ovarian cancer: increasing option-recurrent results. J Clin Oncol. 1997; 15: 2177–2180.
  • 20
    Miller AB, Hoogstraten B, Staquet M. Reporting results of cancer treatment. Cancer. 1981; 147: 207–214.
    Direct Link:
  • 21
    Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996; 14: 1547–1551.
  • 22
    Tobinai K, Kohno A, Shimada Y, et al. Toxicity grading criteria of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 1993; 23: 250–257.
  • 23
    Kaneda N, Nagata H, Furuta T, Yokokura T. Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Res. 1990; 50: 1715–1720.
  • 24
    Le Roy AF, Wehling ML, Sponseller HL, et al. Analysis of platinum in biological materials by flameless atomic absorption spectrophotometry. Biochem Med. 1977; 18: 184–191.
  • 25
    Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, Ratain MJ. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 1994; 54: 3723–3725.
  • 26
    Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981; 9: 503–512.
  • 27
    Takeda K, Negoro S, Takefuji N, et al. Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2001; 48: 104–108.
  • 28
    Sato M, Ando M, Minami H, et al. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer. Cancer Chemother Pharmacol. 2001; 48: 481–487.
  • 29
    de Jonge MJA, Verweij J, Planting AST, et al. Drug-administration sequence does not change pharmacodynamics and kinetics of irinotecan and cisplatin. Clin Cancer Res. 1999; 5: 2012–2017.
  • 30
    Sugiyama T, Yakusiji M, Kamura T, et al. Irinotecan and cisplatin as first line chemotherapy for advanced ovarian cancer. Oncology. 2002; 63: 16–22.
  • 31
    Sugiyama T, Yakushiji M, Nishida T, et al. Irinotecan combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett. 1998; 128: 211–218.
  • 32
    Kigawa J, Takahashi M, Minagawa Y, et al. Topoisomerase-1 activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer. Int J Cancer. 1999; 84: 521–524.
    Direct Link:
View Full Article (HTML) Get PDF (187K)